Valeant Pharmaceuticals International VRX
Citron's 'next Enron' attack on Valeant overstates the risk: Philidor is only ~6% of sales, and even written off, VRX trades at ~8x 2016 cash EPS with 135%+ long-term upside.
Thesis
Pershing Square defends its Valeant position after a ~50% stock drop triggered by Hillary Clinton's September price-gouging tweets and Citron Research's October-21 'next Enron' report alleging channel stuffing via specialty pharmacy Philidor. Ackman argues Philidor represented only 5.9% of YTD revenue, that Citron's channel-stuffing claim is verifiably false, and that even excluding 100% of Philidor's contribution Valeant trades at ~8x 2016 cash EPS of ~$14. A conservative long-term model assuming no further acquisitions still produces 62-116% upside; a more realistic model compounding acquisitions at 7x EBITDA yields 135-214% present-value upside by 2019. Drawing an explicit analogy to American Express after the 1963 Salad Oil Scandal — when a young Warren Buffett put 40% of his fund into AmEx — Ackman closes on the Buffett maxim to be greedy when others are fearful.
SCQA
Valeant is a ~$40bn-market-cap multinational specialty pharmaceutical company built by CEO Mike Pearson since 2008 via disciplined M&A, leverage and decentralization, with leading franchises in Bausch & Lomb, dermatology, gastroenterology and emerging markets.
Hillary Clinton's price-gouging tweets plus Citron's October-21 'next Enron' report alleging channel stuffing through Philidor — compounded by Valeant's chronic under-investment in IR, PR and government relations — crashed the stock ~50% in six weeks.
Terminate Philidor, complete the board's ad hoc compliance review, invest aggressively in transparency and investor/government relations, and trust the resilient franchise portfolio to deliver floor 2016 EBITDA guidance of $7.5bn.
Even conservatively zeroing Philidor, VRX trades at ~8x 2016 cash EPS of ~$14; the long-term model yields $262-350 present value versus $111.50 today — 135-214% upside over four years.
The three reasons
- 1
Philidor was only ~5.9% of YTD sales; Citron's channel-stuffing claim is verifiably false
- 2
Even zeroing all of Philidor, VRX trades at ~8x 2016 cash EPS of ~$14
- 3
Like AmEx after the 1963 Salad Oil Scandal, franchise resilience will prevail
Primary demands
- Terminate the Philidor relationship and develop new specialty-pharmacy channel partners
- Complete the ad hoc board committee's review of Philidor compliance
- Dramatically increase investor, public and government relations transparency
- Stay the course on the decentralized, M&A-driven capital allocation framework
KPIs cited
Pattern membership
Precedents cited
- American Express / Great Salad Oil Scandal (1963) — Buffett's 40%-of-fund AmEx bet
- Novartis specialty-pharmacy kickback case (DOJ settlement Oct-2015, $390mm)
- Large pharma compliance track record (GSK, Pfizer, Merck, J&J fines) showing that even major penalties do not impair franchises
Composition what's on the 38 slides
Slide gallery ·
Notes
Atypical activist deck: Pershing is long VRX and defending CEO Mike Pearson against Citron Research's 'next Enron' short report (Oct-21-2015) and Hillary Clinton's price-gouging tweets — not attacking management. Campaign phase coded 'follow_up' because it is a subsequent public update on an existing long position. Thesis types are 'undervaluation' and 'multiple_rerating'; no fraud_exposure despite the short-seller context (Pershing rebuts the fraud narrative). Closing rhetoric leans heavily on the AmEx / 1963 Salad Oil Scandal / Buffett analogy — a memorable contrarian-playbook pattern worth extracting. Cover page does not explicitly list Ackman as author but the call was led by him and the deck was prepared under his direction; author_name set accordingly. Stake not disclosed as a percentage in the deck (only share-lot accumulation history).